ArticlePharmacology research & perspectives2022

Atezolizumab plus carboplatin and nab-paclitaxel versus carboplatin and nab-paclitaxel as treatments for Chinese, treatment-naïve, stage IV, non-squamous, non-small-cell lung cancer patients: A retrospective analysis.

Yingkai Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.